규제 업데이트
2026년 8월 30일•1분 읽기
MHRA March 2024 Letters and Medicine Recalls Summary
A brief overview of letters and notifications sent to UK healthcare professionals about medicines and medical devices in March 2024.
규제 업데이트
2026년 8월 27일•1분 읽기
MHRA flags increased wear and corrosion risk in cobalt‑chrome modular neck hip stems
The UK Medicines and Healthcare products Regulatory Agency (MHRA) reports higher wear, corrosion and possible revision surgery risks for cobalt‑chrome modular neck hip stem components.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Issues Reminder on Neuropsychiatric Risks of Montelukast
MHRA reminds prescribers that montelukast can cause neuropsychiatric reactions, including sleep disorders, in patients of all ages.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Issues April 2024 Update on Medicines and Device Safety Communications
The MHRA released a summary of letters and notifications sent to healthcare professionals in April 2024 regarding medicines, medical devices, and two new Device Safety Information pages.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Summary of Recent Medicine and Device Safety Letters
The MHRA has released a summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
1
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Issues New Safety Measures: Topiramate Contraindicated in Pregnancy
Topiramate is now contraindicated in pregnancy and in women of childbearing potential unless a Pregnancy Prevention Programme is followed, per MHRA review.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Drug Safety Update: June 2024 Letters and Notifications
The MHRA released a summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA warns Epimax ointments may cause ocular surface toxicity if applied to face
MHRA advises against prescribing Epimax Ointment or Epimax Paraffin‑Free Ointment for facial use due to reports of eye injury.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA August 2024 Drug Safety Update: Summary of Letters and Recalls
The MHRA released a summary of letters and notifications sent to healthcare professionals in August 2024 regarding medicines and medical devices.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA Drug Safety Update: September 2024 Letters & Recalls
MHRA released a summary of recent letters and notifications to healthcare professionals concerning medicines and medical devices for September 2024.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA advises blood pressure monitoring for bromocriptine patients
MHRA safety review recommends blood pressure monitoring for patients on bromocriptine following a Yellow Card report.
규제 업데이트
2026년 8월 25일•1분 읽기
MHRA reminds HCPs to discuss GLP‑1RA side effects with patients
Healthcare professionals should inform patients of common and serious side effects of GLP‑1 receptor agonists.